A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections Clinical Trial

Official title:

A Phase 1/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05089630
• Other study ID #: 209976
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 14, 2021
• Est. completion date: June 19, 2029

Study information

• Verified date: February 2024
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens adjuvanted, regardless of baseline CMV sero-status. This FTiH study will be conducted in healthy adults 18 to 50 years of age, in which the 4 dose levels of the vaccine will be administered in a step-wise dose escalation manner, based upon safety adjudication.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 329
• Est. completion date: June 19, 2029
• Est. primary completion date: June 19, 2029
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

For participants in EPOCH 1:

• Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
• Written informed consent obtained from the participant prior to performance of any study specific procedure.
• A healthy adult (woman or man), 18 to 50 years of age at the time of the first study intervention administration.
• Healthy participants as established by medical history and clinical examination before entering the study.
• Participants who are women of non-childbearing potential may be enrolled in the study.
• Participants who are women of child-bearing potential may be enrolled in the study, if

the participant:

• has practiced adequate contraception for 30 days prior to study intervention administration, and
• has a negative pregnancy test on the day of study intervention administration and
• has agreed to continue adequate contraception during the entire treatment period and for 3 months after completion of the study intervention administration series.
• Participants who agree to take appropriate infection control measures to prevent becoming infected with SARS-CoV2 during the study.
• Participants who initially fail screening due to COVID-19 infection may be re-screened and included in the study, within the screening window period.
• Participants with signs/symptoms suggestive of active COVID-19 (i.e., fever, cough, etc.) should be isolated for the time period recommended by CDC since the signs/symptoms started, and symptoms have resolved.
• Participants with known COVID-19 positive contacts should be quarantined for the time period since exposure recommended by CDC since the exposure and the participant remains symptom free or COVID test negative.
• Participants who are diagnosed with COVID-19 may receive their subsequent CMVsu vaccination dose provided they have no fever, and their condition is considered stable by the investigator (e.g., there may be mild lingering cough, but no shortness of breath or difficulty breathing) within the original schedule.
• Participants who initially fail screening due to other active infections may be re screened within the screening window period and included in the study, if they no longer have signs or symptoms of active infection in the judgment of the site investigator.
• If a participant has equivocal results on CMV serodiagnostic screening test, they are permitted to be re-screened if within the 60-day screening window. Flexibility in safety blood evaluations will be permitted within the Schedule of activities time intervals.

For participants in EPOCH 2:

• Participation in Epoch 1 of the study with receipt of 2 or 3 doses of study intervention.
• Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., return for follow-up visits).
• Written informed consent obtained from the participant prior to performance of any study specific procedure.
• Participants with active infections, including COVID-19 may be rescheduled within the window period, if they no longer have signs or symptoms of active infection in the judgment of the investigator. Exclusion Criteria: For participants in EPOCH 1: Medical conditions
• Known documented medical history of or viral hepatitis B or C infection.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
• Any confirmed or suspected immunosuppressive or immunodeficient condition.
• Family history of congenital or hereditary immunodeficiency.
• History of or current autoimmune disease.
• Lymphoproliferative disorder or malignancy within previous 5 years (excluding effectively treated non-melanotic skin cancer).
• Hypersensitivity to latex.
• Major congenital defects
• Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality.
• Recurrent history or uncontrolled neurological disorders.
• Any hematological or biochemical abnormality.
• Any acute or chronic, clinically significant disease or pulmonary, cardiovascular, hepatic, or renal functional abnormalities.
• Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
• Participants with symptoms suggestive of active COVID-19 infection are excluded.
• Participants with known COVID-19 positive contacts within the past 14 days should be excluded for at least 14 days since the exposure and the participant remains symptom free.
• Any other clinical condition that, might pose additional risk to the participant due to participation in the study. Prior/Concomitant therapy
• Any history of or planned receipt of a CMV vaccine other than the study intervention at any time point.
• Use of other investigational/non-registered product during the period beginning 30 days before the first dose, or their planned use during the study period.
• Planned administration of any vaccine not foreseen by the study protocol 30 days before and 30 days after each study vaccination administration any licensed influenza vaccine administered > 15 days before/ after vaccination.
• In case of extraordinary emergency mass vaccination for an unforeseen public health threat the time period can be reduced if necessary, for that mass vaccination vaccine, which may be under emergency use authorization.
• COVID-19 vaccines should be given at least 30 days before or after administration of a GSK study vaccine. This interval can be reduced to > 14 days, if emergency vaccination is recommended by public health authorities.
• Candidate COVID-19 vaccines are not allowed.
• Chronic administration of immunosuppressants or other immune-modifying drugs within 3 months prior to the vaccine dose. Inhaled and topical steroids are allowed.
• Administration of long-acting immune-modifying drugs at any time during the study period.
• Administration of immunoglobulins and/or any blood products during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration during the study period. Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention Other exclusions
• Pregnant or lactating women. If a woman becomes pregnant/lactating during the study, she will be excluded from subsequent vaccine doses but will be followed for safety.
• Women planning to become pregnant or planning to discontinue contraceptive precautions before 3 months after last study vaccination.
• Participants with known high exposure risk for CMV transmission, to enable distinction of true vaccine effect from natural infection during the study.
• Planned move to a location that will prohibit participating in the trial until study end.
• Participants with current chronic alcohol consumption and/or drug abuse as defined by Diagnostic and Statistical Manual of Mental Disorders 5th edition.

For Participants in EPOCH 2:

• Any confirmed/suspected immunosuppressive/immunodeficient condition including malignancy (excluding effectively treated non-melanotic skin cancer).
• Known documented medical history of HIV or hepatitis B or C.
• Use or anticipated use of immunosuppressants/ or immune modifying drugs during the whole study period.
• Hypersensitivity to latex.
• Any acute or chronic clinically significant disease that , might pose additional risk to the participant due to participation in the study.
• Any history of planned receipt of a CMV vaccine other than the study intervention (CMVsu) at any time point.
• Use of other investigational or non-registered product or their planned use during the study period.
• Concurrently participating in another clinical study, in which the participant has been/ will be exposed to an investigational or a/ non-investigational intervention.

Related Conditions & MeSH terms

• Cytomegalovirus Infections

Intervention

Biological:
• Pentamer (low)/gB(low)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
• Pentamer (med)/gB(low)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
• Pentamer (med)/gB(med)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
• Pentamer (high)/gB(med)/Adjuvant vaccine
Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.

Combination Product:
• Placebo (saline)
Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.

Locations

Country	Name	City	State
United States	GSK Investigational Site	Anaheim	California
United States	GSK Investigational Site	Austin	Texas
United States	GSK Investigational Site	Cedar Park	Texas
United States	GSK Investigational Site	Dearborn Heights	Michigan
United States	GSK Investigational Site	Hallandale Beach	Florida
United States	GSK Investigational Site	Las Vegas	Nevada
United States	GSK Investigational Site	League City	Texas
United States	GSK Investigational Site	Lexington	Kentucky
United States	GSK Investigational Site	Lincoln	Nebraska
United States	GSK Investigational Site	Long Beach	California
United States	GSK Investigational Site	Los Angeles	California
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	New York	New York
United States	GSK Investigational Site	Newark	New Jersey
United States	GSK Investigational Site	Omaha	Nebraska
United States	GSK Investigational Site	Puyallup	Washington
United States	GSK Investigational Site	Secaucus	New Jersey
United States	GSK Investigational Site	Springfield	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants reporting solicited administration site events	The solicited administration site events include pain, redness and swelling.	Within 7 days (the day of dose and 6 subsequent days) after each dose (vaccines administered on Day 1, Day 61 and Day 181)
Primary	Number of participants reporting solicited systemic events	The solicited systemic events include fever, myalgia, fatigue, arthralgia and headache. The preferred location for measuring temperature is the oral cavity. Fever is defined as body temperature =38.0°C/100.4°F by any route.	Within 7 days (the day of dose and 6 subsequent days) after each dose (vaccines administered on Day 1, Day 61 and Day 181)
Primary	Number of participants reporting unsolicited adverse events (AEs) within 7 days after each dose	An unsolicited AE is an AE that was not included in a list of solicited events using a Participant Diary. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.	Within 7 days (the day of dose and 6 subsequent days) after each dose (vaccines administered on Day 1, Day 61 and Day 181)
Primary	Number of participants reporting serious adverse events (SAEs) within 7 days after each dose	A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or is an abnormal pregnancy outcome.	Within 7 days (the day of dose and 6 subsequent days) after each dose (vaccines administered on Day 1, Day 61 and Day 181)
Primary	Number of participants reporting unsolicited AEs up to 30 days after each dose	An unsolicited AE is an AE that was not included in a list of solicited events using a Participant Diary. Unsolicited events must have been spontaneously communicated by a participant who has signed the informed consent. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.	Up to 30 days after each dose (vaccines administered on Day 1, Day 61 and Day 181)
Primary	Number of participants reporting SAEs up to 30 days after each dose	A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or is an abnormal pregnancy outcome.	Up to 30 days after each dose (vaccines administered on Day 1, Day 61 and Day 181)
Primary	Number of participants reporting medically attended AEs (MAEs) up to 30 days after each dose	A MAE is an AE for which the participants received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.	Up to 30 days after each dose (vaccines administered on Day 1, Day 61 and Day 181)
Primary	Number of participants reporting hematological and biochemical laboratory abnormalities on Day 1	The percentage of participants having hematology and biochemistry results below or above the laboratory normal ranges are tabulated by time point.	At Day 1
Primary	Number of participants reporting hematological and biochemical laboratory abnormalities on Day 8	The percentage of participants having hematology and biochemistry results below or above the laboratory normal ranges are tabulated by time point.	At Day 8
Primary	Number of participants reporting hematological and biochemical laboratory abnormalities on Day 61	The percentage of participants having hematology and biochemistry results below or above the laboratory normal ranges are tabulated by time point.	At Day 61
Primary	Number of participants reporting hematological and biochemical laboratory abnormalities on Day 68	The percentage of participants having hematology and biochemistry results below or above the laboratory normal ranges are tabulated by time point.	At Day 68
Primary	Number of participants reporting hematological and biochemical laboratory abnormalities on Day 181	The percentage of participants having hematology and biochemistry results below or above the laboratory normal ranges are tabulated by time point.	At Day 181
Primary	Number of participants reporting hematological and biochemical laboratory abnormalities on Day 188	The percentage of participants having hematology and biochemistry results below or above the laboratory normal ranges are tabulated by time point.	Day 188
Secondary	Number of participants reporting unsolicited AEs from Dose 1 to end of EPOCH 1 (Month 18)	An unsolicited AE is an AE that was not included in a list of solicited events using a Participant Diary. Unsolicited events must have been spontaneously communicated by a participant who has signed the informed consent. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.	From Dose 1 (Day 1) to end of EPOCH 1 (Month 18)
Secondary	Number of participants reporting MAEs from Dose 1 to end of EPOCH 1 (Month 18)	A MAE is an AE for which the participants received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.	From Dose 1 (Day 1) to end of EPOCH 1 (Month 18)
Secondary	Number of participants reporting SAEs from Dose 1 to end of EPOCH 1 (Month 18)	A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or is an abnormal pregnancy outcome.	From Dose 1 (Day 1) to end of EPOCH 1 (Month 18)
Secondary	Number of participants reporting potential immune-mediated disease (pIMDs) from Dose 1 to end of EPOCH 1 (Month 18)	PIMDs include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.	From Dose 1 (Day 1) to end EPOCH 1 (Month 18)
Secondary	Neutralizing antibodies (nAbs) titers against epithelial cell infection	The humoral immune response is measured in terms of nAbs against epithelial cell infection and expressed as geometric mean titers (GMT). Serological assays for the determination of antibodies against CMV are performed by neutralization assay.	On the day of each dose (Day 1, Day 61, Day 181), 30 days post each dose (Day 31, Day 91 and Day 211), 6- and 12-months post-Dose 3 (Day 361, Day 546) [EPOCH 1] and Year 2.5, Year 3.5, Year 4.5, Year 5.5 [EPOCH 2]
Secondary	Anti-pentamer immunoglobulin G (IgG) and anti-gB IgG concentrations	The vaccine-induced anti-gB and anti-pentamer humoral immune response is measured in terms of anti-pentamer IgG and anti-gB IgG geometric mean concentrations (GMCs) determined by enzyme linked immunosorbent assay (ELISA) and expressed in EU/ml.	On the day of each dose (Day 1, Day 61, Day 181), 30 days post each dose (Day 31, Day 91 and Day 211), 6- and 12-months post-Dose 3 (Day 361, Day 546) [EPOCH 1] and Year 2.5, Year 3.5, Year 4.5, Year 5.5 [EPOCH 2]
Secondary	CMV specific cluster of differentiation (CD)4+ T-cells frequency	The vaccine-induced cellular immune response is measured in terms of CD4+ T-cells frequency per million PBMCs.	Before each dose (Day 1, Day 61, Day 181), 1-month post-dose 2 and dose 3 (Day 91, Day 211), 6- and 12-months post-dose 3 (Day 361, Day 546) [EPOCH 1] and Year 2.5, Year 3.5, Year 4.5, Year 5.5 [EPOCH 2]
Secondary	CMV specific CD8+ T-cells frequency	The vaccine-induced cellular immune response is measured in terms of cytokine expressing CD4+ T-cells per million PBMCs.	Before each dose (Day 1, Day 61, Day 181), 1-month post-dose 2 and dose 3 (Day 91, Day 211), 6- and 12-months post-dose 3 (Day 361, Day 546)
Secondary	Concordance of CMV sero-status results	Concordance of CMV sero-status results (positive/negative) obtained with both assays will be assessed at screening visit (Day -59) and 1 month post-dose 1 and 2 (D31, D91).	At screening (Day -59) and 1 month post-dose 1 and 2 (Day 31, Day 91).
Secondary	Individual anti-tegument IgG result	The individual anti-tegument IgG result (positive/negative) assessed by ELISA is obtained at Month 6 -Month 7 -Month 12 -Month 18 [EPOCH] 1 and Year 2.5, Year 3.5, Year 4.5, Year 5.5 [EPOCH 2]	At Month 6-Month 7-Month 12-Month 18 [EPOCH] 1 and Year 2.5, Year 3.5, Year 4.5, Year 5.5 [EPOCH 2]